
How Can You Manage Negative Facebook Comments?
Odds are that you’re going to be more likely to deal with haters than fans on a Facebook page, according to a study. But smart moderation tactics can help defuse issues before they get out of hand.
BALTIMORE, MD, February 27, 2025 – A new study published in the INFORMS journal Management Science reveals that unlimited mobile data plans may be a key solution to reducing digital inequality. The research shows that low-income and rural households benefit the most when data caps are removed – particularly in their ability to access educational content.
Contentious minerals deal has sparked a war of words between Trump and Zelensky, and could be announced later this week
Americans have probably heard the word “tariffs” more in the past month than in the past four years — and for good reason. Tariffs are central to President Donald Trump’s economic playbook, despite opposition from mainstream economists and trade experts.
An audio journey of how data and analytics save lives, save money and solve problems.
Ashley Smith
Public Affairs Coordinator
INFORMS
Catonsville, MD
[email protected]
443-757-3578
Explore our resources for multiple topics including:
Odds are that you’re going to be more likely to deal with haters than fans on a Facebook page, according to a study. But smart moderation tactics can help defuse issues before they get out of hand.
North Carolina is among the best-performing U.S. states when it comes to distributing vaccines evenly among Black and white residents. That’s partly because the state is by far the best at collecting demographic data. About 11% of North Carolina’s Black population has received at least one shot, compared with 17% of the state’s white residents, the Bloomberg Vaccine Tracker shows. That puts North Carolina in fourth place for the smallest spread between the two groups among states with the most comprehensive data sets. Other states might be doing as well or better than North Carolina in terms of equality, though huge numbers of incomplete records obscure the national picture.
The U.S. government has invested billions of dollars in manufacturing, used a wartime act dozens of times to boost supplies and yet there’s still not enough COVID-19 vaccine on the way to meet demand — or even the government’s own goals for national immunization. President Joe Biden, in remarks at the National Institutes of Health this month, said the nation is “now on track to have enough supply for 300 million Americans by the end of July.” But at the current rate of production, Pfizer and Moderna will miss their targets of providing at least 100 million doses each by the end of March, let alone 200 million more doses each has promised by July.
Portland resident Richard Clarke, 70, isn’t sure if he’s officially registered to enter a weekly COVID-19 vaccination lottery for appointments available at the Oregon Convention Center. He said after registering at getvaccinated.oregon.gov, he hasn’t received an email or a text confirming that he’s in the pool of eligible residents -- even though the state has publicly said everyone who registers will. He also called 211 to verify, but the representative wasn’t able to give him an answer. Clarke said he’s also uneasy because contrary to what state and local officials announced more than a week ago, the state website still says, “This tool does not allow you to schedule a vaccination appointment.”
More than 50 million Americans have received at least one dose of either the Pfizer or Moderna COVID-19 vaccine. So far, Americans have been largely brand-agnostic, but that’s about to change as a new vaccine rolls out. The Johnson & Johnson vaccine has been hailed as a game changer. It requires only a single dose rather than two doses spaced weeks apart, and it does not need freezer storage, making it a natural fit for hard-to-reach rural areas and underserved communities with limited access to health care and storage facilities. But while many people are excited about the prospects of only one shot, the new vaccine is also getting backlash. Part of that is coming from lack of clarity about the vaccines’ efficacy numbers, and part of it is more nuanced.
OR/MS Today is the INFORMS member magazine that shares the latest research and best practices in operations research, analytics and the management sciences.
Access OR/MS Today MagazineAnalytics magazine showcases articles and research reports based on big data, AI, machine learning, data analytics and other new-age technologies.
Access Analytics Magazine